Neuroretina
Издатель: Springer Nature · 19 статей
-
Lirafugratinib (Lyrfigtu ® ): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma
Fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements are validated oncogenic drivers in intrahepatic cholangiocarcinoma. The US FDA recently approved the highly selective inhibitor lirafugratinib (Lyrfigtu ® ) for adult...
-
Design, synthesis, and biological evaluation of novel p-tert -Butylcalix[4]arene derivatives bearing maleimide units as potential anticancer agents
In this study, a novel series of seven p -tert-butylcalix[4]arene derivatives functionalized with lower-rim aminomaleimide moieties (4a–g) was designed, synthesized, and evaluated for its in vitro antiproliferative potential. Initial...
-
New diterpenoids from Croton L. species (2019–2025): structural diversity and bioactivity
Croton L. (Euphorbiaceae) is recognized as one of the richest botanical sources of structurally diverse diterpenoids with a remarkable range of biological activities. These compounds display an exceptional diversity of carbon skeletons,...
-
Mushroom-derived metabolites: a promising source of novel lead compounds for pharmaceutical and functional food applications
Edible and medicinal mushrooms are important sources of novel bioactive natural products, abundant in terpenoids, sterols, alkaloids, peptides, and other bioactive substances. These compounds exhibit a variety of physiological...
-
Brepocitinib (Lisraya ® ), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults
Dermatomyositis is a rare systemic autoimmune disease characterized by chronic inflammation, progressive muscle weakness, and prominent cutaneous manifestations, with limited approved treatment options. Brepocitinib (Lisraya ® ), an...
-
Zidebactam as a new approved β-Lactamase inhibitor with intrinsic antibacterial activity via PBP2 binding
Antimicrobial resistance continues to challenge the clinical efficacy of established antibiotics, highlighting the need for innovative therapeutic strategies. Cefepime/zidebactam combines a fourth-generation cephalosporin with a novel...
-
Remibrutinib (Rhapsido ® ), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria
Remibrutinib (Rhapsido ® ) is a selective, orally bioavailable covalent inhibitor of Bruton’s tyrosine kinase (BTK), approved in 2025 for the treatment of adult chronic spontaneous urticaria (CSU) uncontrolled by H 1 -antihistamines. By...
-
Camizestrant (Etcamah ® ): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative tumors are the most common types of breast cancer. Mutation of ESR1 complicates their therapy. On September 04, 2026, camizestrant (Etcamah ® )...
-
Small-molecule ferroptosis inducers and sensitizers in anticancer drug discovery: medicinal chemistry, structure–activity relationships, and translational perspectives
Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation, proceeds independently of caspase activation and can remain effective in apoptosis-resistant and mesenchymal-like tumor populations,...
-
Azole chroman-4-one, tetralone and chromen-4-one derivatives: synthesis, Mycobacterium tuberculosis CYP121A1 enzyme inhibition and antimycobacterial activity
Tuberculosis (TB) remains a major global health challenge, driven by the emergence of drug-resistant Mycobacterium tuberculosis ( Mtb ) strains and the limitations of existing treatment regimens. Twenty CYP enzymes unique to Mtb...
-
Coumarin scaffolds in breast cancer research: derivatives, hybrids, and therapeutic potential
Breast cancer remains one of the most common cancers worldwide and continues to present major therapeutic challenges due to tumor diversity, drug resistance, and recurrence. These issues highlight the need for new treatments with better...
-
Structure-based discovery of acridone alkaloids as disruptors of the HEG1–KRIT1 protein–protein interaction in cerebral cavernous malformation signaling
The HEG1–KRIT1 interaction is essential for endothelial cerebral cavernous malformation complex localization and signaling, making this interface a relevant target for chemical disruption. This study aimed to identify acridone alkaloids...
-
Bicyclononane-2,8-bis(trifluoromethyl)quinoline hybrids: synthesis, antiplasmodial and antitrypanosomal activity
With the aim to design dual-acting antiprotozoals, a set of hybrid-molecules was prepared. Amino-substituted 2-aza- and 3-azabicyclo[3.2.2]nonanes with antiplasmodial and antitrypanosomal activity were linked via aminoalkyl linkers to...
-
From danger to resolution: targeting purinergic signaling in CNS diseases
The central nervous system (CNS) is a dynamic immunological environment, where specialized interfaces, immune reservoirs, and metabolic clearance pathways, such as the glymphatic system, orchestrate immune surveillance and homeostasis....
-
Vepdegestrant: the first FDA-approved oral PROTAC and a milestone in targeted protein degradation
Vepdegestrant (ARV-471, Veppanu) represents an important milestone in targeted protein degradation (TPD) as the first FDA-approved heterobifunctional proteolysis-targeting chimera (PROTAC). Designed to selectively degrade estrogen...
-
Design and biological evaluation of sulfonamide–chalcone hybrids with in vitro tumor-selective cytotoxicity against oral squamous cell carcinoma: SAR, QSAR, and in silico ADME studies
Multidrug resistance and off-target toxicity remain major challenges in the treatment of oral squamous cell carcinoma (OSCC). In this study, sulfonamide-chalcone hybrids were designed by combining the chalcone scaffold with a...
-
Baxdrostat (Baxfendy ® ), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension
Despite the availability of multiple antihypertensive therapies, many patients remain unable to achieve adequate blood pressure control. Excess aldosterone is a key contributor to resistant and uncontrolled hypertension. Baxdrostat...
-
Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies
Glyoxalase I (Glo-I) enzyme is a validated anticancer target due to its role in methylglyoxal detoxification and its association with tumor progression and drug resistance. Inhibition of Glo-I promotes the accumulation of toxic...
-
Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications
Hepatocellular carcinoma (HCC) is among the most prevalent malignancies and remains a leading cause of cancer-related mortality worldwide. Because early-stage HCC often has a silent clinical course and current surveillance strategies...